MariMed Inc. reports news on its multi-state cannabis operating platform, including cultivation, production, branded consumer products and retail dispensaries. Company updates commonly cover financial results, earnings-call schedules, wholesale distribution, branded product activity and retail operations tied to names such as Betty's Eddies, Bubby’s Baked, InHouse, Nature’s Heritage, Vibations and Thrive Dispensary.
Recurring developments also include capital-structure actions, preferred-stock obligations, hemp-derived THC product launches, cannabis regulatory commentary and community initiatives associated with the company's dispensary and brand portfolio.
MariMed (MRMD) is renewing its Betty’s Eddies collaboration with Keep A Breast Foundation for a fourth annual breast cancer awareness campaign. The campaign kicks off during the week of September 24, 2026, ahead of October’s Breast Cancer Awareness Month. Limited-time pink packaging for Ache Away Eddies fruit chews will be available across Massachusetts, Maine, Maryland, Illinois and Delaware. The packaging promotes the foundation’s free breast-health app. Ache Away Eddies contains CBD, CBC and THC, along with turmeric, piperine and vitamin E.
This year’s campaign adds a purchase round-up initiative at all 12 Thrive dispensary locations in participating states. Customers will be invited to round up their purchases, with all proceeds from the program benefiting Keep A Breast’s breast cancer awareness and education initiatives.
MariMed (MRMD) filed a definitive proxy statement and set a Special Meeting to seek stockholder approval for a proposed reverse stock split of its common stock.
The Reverse Stock Split is intended to give MariMed more flexibility to meet minimum share price and other requirements for a potential listing on a U.S. national securities exchange. If approved, the Board may implement a split ratio between 1-for-50 and 1-for-100, or decide not to proceed if it deems the action not in stockholders’ best interests. No fractional shares would be issued; affected stockholders would receive cash in lieu of fractions.
The Special Meeting will be held virtually on October 28, 2026, at 9:30 a.m. ET. Stockholders of record as of the close of business on September 4, 2026 are entitled to vote. The company cautions there is no assurance the Board will effect the split, that listing eligibility will be achieved, or that any trading price or liquidity improvement will be sustained.
MariMed (MRMD) will open its new Thrive Dispensary Columbus on September 18, 2026, marking its 14th Thrive location across five states and second in Ohio.
The store is on Columbus’s east side at 2025 Brice Road, where a former bank has been converted into a modern cannabis retail destination featuring a drive-through window and dedicated curbside parking. The opening supports the company’s strategy to grow its product and retail brands in high‑growth markets. Ohio’s legal cannabis market generated $111 million in sales in July 2026, up 22% year over year, underscoring the state’s expansion potential.
MariMed (CSE/OTCQB: MRMD) reported second quarter 2026 revenue of $41.9 million, up from $39.5 million a year earlier and the highest quarterly revenue in its history. GAAP gross margin was 39%, while non-GAAP gross margin was 40%. The Company posted a GAAP net loss of $3.6 million versus a $1.4 million loss in Q2 2025, and non-GAAP net loss of $2.4 million versus non-GAAP net income of $0.3 million. Non-GAAP adjusted EBITDA was $3.9 million with a 9% margin, compared with $4.8 million and a 12% margin last year. For the first half of 2026, revenue reached $81.4 million and operating cash flow was $3.2 million, up from $1.6 million in the prior-year period.
Wholesale revenue grew 6% sequentially and retail revenue 7% sequentially, with branded product distribution expanding to 85% of available storefronts on a trailing 12‑month basis. Cash, cash equivalents and restricted cash totaled $8.4 million at June 30, 2026, total assets were $197.2 million, and total liabilities $147.1 million.
MariMed (CSE:MRMD, OTCQB:MRMD) is launching limited-edition autumn cannabis edibles across its core markets. The company is introducing Betty’s Eddies™ Perk Up, Pumpkin Spice Latte Swirl fruit chews and bringing back Bubby’s Baked™ Pumpkin Bread Bites, positioned around strong consumer demand for seasonal pumpkin flavors.
The Perk Up chews feature a pumpkin spice latte taste and an uplifting blend of 5mg THC, 5mg CBC, and 5mg CBG per piece. Bubby’s Baked Pumpkin Bread Bites are made with real pumpkin and warm spices, each infused with a precise full-spectrum cannabis dose. According to MariMed, these products will be available for adult-use and medical consumers at its Thrive Dispensaries and select retailers in Massachusetts, Maryland, Delaware, Illinois, and, for the Perk Up chews, select Maine dispensaries.
MariMed (CSE: MRMD, OTCQB: MRMD) announced it will report its second quarter 2026 financial results on August 12, 2026 after market close. Management will hold a conference call on August 13, 2026 at 8:00 a.m. EDT to discuss the results, with a live webcast and playback available via the company’s Investor Relations website.
MariMed (MRMD), through its Betty’s Eddies brand, introduced Betty’s Bite-A-Mins, a daily wellness chew combining full-spectrum cannabis, 30mg of CBD, and the recommended daily allowance of vitamins C, D3, and Zinc in a tropical smoothie flavor. The new chews will be sold at MariMed’s Thrive Dispensary locations and other licensed cannabis retailers across Massachusetts, Maryland, Illinois, Delaware, Maine, and Rhode Island, expanding the brand’s core lineup of effect-focused cannabis fruit chews.
MariMed (CSE/OTCQB: MRMD) brand Nature’s Heritage launched “The Nose Knows,” a science-backed cannabis consumer education campaign. It teaches shoppers to choose products by aroma rather than THC percentage, grouping strains into six aroma-and-effect categories and using immersive in-store experiences plus an online “Find Your Flower” quiz.
MariMed (MRMD) announced it has submitted applications to the DEA to register certain state-licensed medical cannabis operations. This registration is required to qualify for protections linked to cannabis’ federal rescheduling to Schedule III, including federal safe harbor and relief from IRS Section 280E restrictions.
MariMed (MRMD) reported first quarter 2026 revenue of $39.5 million, up from $37.9 million in 2025. GAAP net loss was $3.8 million, with non-GAAP net loss of $3.2 million. Non-GAAP adjusted EBITDA was $3.6 million, a margin of 9%.
The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity to 4.6 years and removing a February 26, 2026 mandatory conversion date, which it says reduces near-term refinancing risk and supports liquidity.